Immutep Ltd has released a press release.
Efti to be evaluated in new triple combination therapy trial
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Immutep
- Immutep secures commitments for A$60 million in a Placement
- Immutep global webcast slides
- Immutep Reveals a New anti-LAG-3 Research Program
- Immutep Reports Positive Data from its TACTI-002 ph 2 trial
- Immutep granted European patent for its LAG-3 candidate Efti
Later from Immutep
- US FDA & IRB approves start of ph2b head & neck cancer trial
- Completion of Share Purchase Plan
- Completion of Placement - Tranche 2
- INSIGHT-003 investigator-initiated trial - 1st patient dosed
- Chinese patent granted for anti-LAG-3 antibody LAG525
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep